gene

OCLN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about OCLN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

813Connections

0Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

OCLN is a gene implicated in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with ALS, Aging, Als. Connected to 387 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	OCLN
Full Name	Occludin
Chromosome	5q13.2
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. ...
Mechanism of Action	Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. Therapeutic approaches would involve either direct protein stabilization or indirect modulation of occludin phosphorylation and trafficking to maintain barrier function.
Primary Expression	Brain endothelial cells, Epithelial tight junctions
Druggability	Low (0.32)
Clinical Stage	Approved
Molecular Weight	65 kDa
Amino Acids	522 aa
Pathways	Autophagy, Blood-Brain Barrier, Circadian Rhythm, Immune Response, Innate Immunity
UniProt ID	Q16625
NCBI Gene ID	4950
Ensembl ID	ENSG00000130940
OMIM	602876
GeneCards	OCLN
Human Protein Atlas	OCLN
Associated Diseases	ALS, ALZHEIMER, Aging, Ataxia
Known Drugs/Compounds	BENVITIMOD, BYF
Interactions	CLDN5, CLDN1, ZO1, MLCK, BECN1, CAV1
SciDEX Target	View Target Profile (10 clinical trials)
KG Connections	813 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: OCLN — AlphaFold Q16625 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    OCLN["OCLN"] -->|"interacts"| CLDN1["CLDN1"]
    OCLN["OCLN"] -->|"interacts"| ZO1["ZO1"]
    OCLN["OCLN"] -->|"interacts"| MLCK["MLCK"]
    OCLN["OCLN"] -->|"co discussed"| APOE["APOE"]
    OCLN["OCLN"] -->|"co discussed"| LRP1["LRP1"]
    OCLN["OCLN"] -->|"co discussed"| LDLR["LDLR"]
    CLDN1_1["CLDN1"] -->|"interacts"| OCLN["OCLN"]
    ZO1_2["ZO1"] -->|"interacts"| OCLN["OCLN"]
    MLCK_3["MLCK"] -->|"interacts"| OCLN["OCLN"]
    CLDN5["CLDN5"] -->|"interacts"| OCLN["OCLN"]
    style OCLN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (497)

Target	Relation	Type	Str
TIGHT_JUNCTION	participates_in	pathway	1.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
OCCLUDIN	encodes	protein	0.95
TIGHT JUNCTION	involved_in	entity	0.95
BLOOD-BRAIN BARRIER	involved_in	entity	0.95
Blood-Brain Barrier	involved_in	process	0.95
Brain Arteriovenous Malformations	biomarker_for	disease	0.90
blood-brain barrier	participates_in	pathway	0.90
Cell Proliferation	inhibits	process	0.88
Cell Migration	inhibits	process	0.88
BLC-PMG	causes	disease	0.87
Tight Junctions	involved_in	process	0.85
Gut Barrier Dysfunction	involved_in	process	0.85
Brain Edema	associated_with	phenotype	0.85
Immune Response	involved_in	process	0.85
LPS-induced lung injury	protects_against	disease	0.80
Brain Arteriovenous Malformations	downregulates	disease	0.80
Cerebral Cortex	expressed_in	brain_region	0.80
unfolded protein response	participates_in	pathway	0.80
oxidative stress response	participates_in	pathway	0.80
occludin	encodes	protein	0.80
EPITHELIAL_BARRIER	regulates	phenotype	0.72
BARRIER_FUNCTION	regulates	phenotype	0.72
KIRC	associated_with	disease	0.72
HCV	regulates	disease	0.72
VIRAL_ENTRY	regulates	pathway	0.72
NEURODEVELOPMENTAL_DISORDER	causes	disease	0.72
autophagy pathway	participates_in	pathway	0.70
endothelial cells	expressed_in	cell_type	0.70
Stroke	activates	disease	0.65
Als	activates	disease	0.65
Ms	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Ms	activates	disease	0.65
Inflammation	activates	disease	0.65
Inflammation	regulates	disease	0.65
Anxiety	activates	disease	0.65
Tumor	regulates	disease	0.65
Depression	activates	disease	0.65
Ms	regulates	disease	0.65
Aging	activates	disease	0.65
Als	inhibits	disease	0.65
Als	protects_against	disease	0.65
Ms	protects_against	disease	0.65
Inflammation	inhibits	disease	0.65
Cancer	expressed_in	disease	0.65
Carcinoma	biomarker_for	disease	0.65
Tumor	expressed_in	disease	0.65
Cirrhosis	expressed_in	disease	0.65
Ms	expressed_in	disease	0.65

Incoming (316)

Source	Relation	Type	Str
ds-83b31ef18d49	data_in	dataset	1.00
Byf	upregulates	drug	0.95
Brain Arteriovenous Malformations	downregulates	disease	0.95
Betulinic Acid	upregulates	compound	0.95
BRAIN ARTERIOVENOUS MALFORMATIONS	downregulates	entity	0.95
miR-193b-5p	inhibits	gene	0.90
KLF11	binds	entity	0.90
Litebamine	upregulates	compound	0.90
LRWE	upregulates	compound	0.90
h-7a8d7379	targets_gene	hypothesis	0.90
h-6c83282d	targets_gene	hypothesis	0.90
Gallic Acid	upregulates	compound	0.88
Ruptured Brain Arteriovenous Malformations	downregulates	phenotype	0.88
Nobiletin	upregulates	compound	0.85
DTG	downregulates	drug	0.85
BDNF-TrkB-PLC/IP3 pathway	activates	pathway	0.80
h-7a8d7379	targets	hypothesis	0.80
h-6c83282d	targets	hypothesis	0.80
Endoplasmic Reticulum Stress	downregulates	process	0.80
CLDN1	co_mentioned_with	gene	0.80
Qingqi Liangying formula	upregulates	drug	0.80
CMVS	activates	protein	0.72
IL4	inhibits	protein	0.72
IL13	inhibits	protein	0.72
BENVITIMOD	activates	drug	0.72
MIR193B5P	inhibits	gene	0.72
CLDN5	co_mentioned_with	gene	0.70
BYF	activates	drug	0.64
MSC	activates	cell_type	0.64
TNF	inhibits	gene	0.64
CXCL2	inhibits	gene	0.60
IL6	inhibits	gene	0.60
ATF4	therapeutic_target	gene	0.60
PPP1R15A	therapeutic_target	gene	0.60
IL12B	inhibits	gene	0.60
XBP1	therapeutic_target	gene	0.60
CXCL1	inhibits	gene	0.60
DDIT3	therapeutic_target	gene	0.60
CLDN5	inhibits	gene	0.60
HSPA5	therapeutic_target	gene	0.60
ACTB	regulates	gene	0.60
CDC42	regulates	gene	0.60
CASP3	regulates	gene	0.60
SQSTM1	associated_with	gene	0.60
TUBB3	associated_with	gene	0.60
STK11	associated_with	gene	0.60
VIM	associated_with	gene	0.60
BECN1	regulates	gene	0.60
HDAC6	associated_with	gene	0.60
GAPDH	regulates	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (2)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.566

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

neurodegeneration | 2026-04-01 | 20 hypotheses Top: 0.617

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

OCLN

Understanding Entity Pages

Summary

Wiki Pages (21)

OCLN — Occludin

Blood-Brain Barrier Dysfunction in Neurodegeneration

Blood-Brain Barrier Biology and Crossing Strategies

Blood-Brain Barrier Breakdown in Neurodegeneration

blood-brain-barrier-endothelial-cells

Blood-Based Biomarkers for Neurodegeneration

Blood Microbial Signatures in Parkinson's Disease

Section 182: Microbiome Metabolomics and SCFA Therapy in CBS/PSP

MLCK Gene

Blood-Brain Barrier

Neurovascular Unit Dysfunction Hypothesis in Parkinson's Disease

pard3

Microbiome Metabolomics and SCFA Therapy for CBS/PSP

Blood-Brain Barrier Penetration Technologies Investment Landscape

IL13 — Interleukin 13

Blood-Brain Barrier in 4R-Tauopathies

Brain Venous Endothelial Cells

Blood-Brain Barrier Breakdown as Primary Disease Driver

Blarcamesine (ALX-001)

Blood-Brain Barrier Dysfunction Pathway

PGAP2